“…Accumulating evidence has shown that REV-ERBs negatively regulate the expression of various proinflammatory molecules such as the cytokine interleukin-6 (IL-6) and the chemokine CCL2, following binding of the synthetic REV-ERB-specific agonists GSK4112 and SR9009 in macrophages (Sato et al, 2014;. A previous finding showed mildly increased mechanical nociceptive sensitivity in REV-ERBα knockout mice (Lee et al, 2016). Furthermore, it is possible that REV-ERBs might be a new target as analgesic for osteoarthritisinduced pain (Das et al, 2018).…”